Get the Stockscreener App
15.58
0.51%
-0.08
After Hours:
15.58
Mineralys Therapeutics Inc stock is traded at $15.58, with a volume of 1.16M.
It is down -0.51% in the last 24 hours and up +11.76% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$15.66
Open:
$15.62
24h Volume:
1.16M
Relative Volume:
0.92
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-5.707
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
-2.38%
1M Performance:
+11.76%
6M Performance:
+22.00%
1Y Performance:
+25.44%
1-Day Range:
$14.74
$15.89
1-Week Range:
$14.74
$16.90
52-Week Range:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
15.58 | 1.04B | 0 | -119.67M | -97.30M | -2.73 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat - MSN
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting - MSN
Mineralys announces late-breaking presentation of data from Launch-HTN trial - Yahoo Finance
Buy Rating for Mineralys Therapeutics: Strong Clinical Results and Growth Prospects Highlight Significant Upside Potential - TipRanks
Mineralys reports outcomes from trial of lorundrostat for hypertension - Yahoo Finance
MLYS: Promising Phase 3 Results for Hypertension Treatment | MLYS Stock News - GuruFocus
Northern Trust Corp Purchases 1,688 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) - The Manila Times
Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension - Nasdaq
These 3 Artificial Intelligence (AI) Stocks Look Cheap Right Now - The Globe and Mail
Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 - marketscreener.com
Mineralys Therapeutics Announces Late-Breaking Presentation - GlobeNewswire
Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan
Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going - sharewise
Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com Australia
Mineralys to present lorundrostat trial data at ESH 2025 By Investing.com - Investing.com South Africa
Mineralys Announces Late-Breaking Presentation Of Phase 3 Launch-HTN Trial - marketscreener.com
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection - The Manila Times
Breakthrough Phase 3 Trial Data: New Drug Takes Aim at Treatment-Resistant Hypertension Crisis - Stock Titan
Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM - MSN
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - Yahoo Finance
Balyasny Asset Management L.P. Takes $219,000 Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MSN
Dimensional Fund Advisors LP Acquires Shares of 16,412 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys plans NDA submission for lorundrostat following pivotal hypertension data and $201M equity raise - MSN
Insider Sell Alert: David Rodman Sells Shares of Mineralys Thera - GuruFocus
HC Wainwright Issues Positive Estimate for MLYS Earnings - Defense World
Mineralys Therapeutics’ Earnings Call: Positive Outlook Amid Challenges - TipRanks
Mineralys Therapeutics (NASDAQ:MLYS) Earns “Buy” Rating from HC Wainwright - Defense World
Transcript : Mineralys Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Guggenheim Adjusts Price Target for Mineralys Therapeutics (MLYS - GuruFocus
Guggenheim Adjusts Price Target for Mineralys Therapeutics (MLYS) | MLYS Stock News - GuruFocus
Mineralys Therapeutics to Present at Bank of America Health Care Conference - MSN
Positive Buy Rating for Lorundrostat Driven by Successful Trials and Future Potential - TipRanks
Mineralys Therapeutics (MLYS) Receives Buy Rating Reiteration fr - GuruFocus
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call Transcript - Insider Monkey
Strong Financial Position and Promising Clinical Results Support Buy Rating for Mineralys Therapeutics - TipRanks
Optimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data Releases - TipRanks
Mineralys Therapeutics Reports Strong Trial Results and Financial Growth - TipRanks
Earnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock rises - Investing.com
Mineralys Therapeutics reports Q1 EPS (79c), consensus (98c) - TipRanks
Mineralys Therapeutics, Inc. SEC 10-Q Report - TradingView
Mineralys Therapeutics Q1 GAAP Loss Widens - marketscreener.com
Mineralys Therapeutics Q1 2025 Earnings Report - MarketBeat
Mineralys Therapeutics stock rises on better-than-expected Q1 results By Investing.com - Investing.com Nigeria
Mineralys Therapeutics stock rises on better-than-expected Q1 results - Investing.com Australia
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):